Lupus & antiphospholipid syndrome
Economic burden of systemic lupus erythematosus and lupus nephritis in France: a nationwide population-based study using the French medico-administrative (SNDS) claims database
Authors' conclusion
The direct extra costs of SLE and LN are substantial in France, particularly for hospitalizations, outpatient medications, consultations, and transportations.
Study context
- Population
- Prevalent systemic lupus erythematosus (SLE) patients in 2019 in the French nationwide health insurance database (SNDS)SLE 1:1 age- and sex-matched to controls
- Exposure
- SLE vs age- and sex-matched non-SLE controls; Lupus nephritis (LN) vs SLE without LN
- SLEn = 29,135
- LNn = 4,357
- Outcome
- Total direct costs (2019 euros) attributable to SLE and LN
Methodological detailsnationwide population-based, age- and sex-matched (1:1) controls, French health insurance claims database (SNDS)
- Nationwide population-based
- Age- and sex-matched (1:1) controls
- French health insurance claims database (SNDS)
Main finding
As reported in the abstract
Median overall direct cost, third-party payer perspective
P < 0.0001
Observational data: associations, not effects.
Further findings
| Outcome | SLE | LN | SLE without LN | Non-SLE controls | P value |
|---|---|---|---|---|---|
| Overall direct cost, societal perspectiveSLE vs Non-SLE controls | 5894 € | — not stated in the abstract | — not stated in the abstract | 2601 € | P < 0.0001 |
| Overall median cost, third-party payer perspectiveLN vs SLE without LN | — not stated in the abstract | median 9800 € | median 3918 € | — not stated in the abstract | P < 0.0001 |
| Overall median cost, societal perspectiveLN vs SLE without LN | — not stated in the abstract | median 11,279 € | median 4950 € | — not stated in the abstract | P < 0.0001 |
— not stated in the abstract
- Overall direct cost, societal perspective — Extra cost vs controls: hospitalizations
- +€1305
- Overall direct cost, societal perspective — Extra cost vs controls: medications
- +€872
- Overall direct cost, societal perspective — Extra cost vs controls: consultations
- +€343
- Overall direct cost, societal perspective — Extra cost vs controls: transportation
- +€193
National extra cost of SLE vs non-SLE controls
- National extra cost
- M€104.9
- Hospitalizations' share of extra cost
- 39.6%
Original publication
Economic burden of systemic lupus erythematosus and lupus nephritis in France: a nationwide population-based study using the French medico-administrative (SNDS) claims database. Joint Bone Spine. Published 30 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →